Stock Exchange & Press Releases 2020

Print Print this release
December 18, 2020

Cerenion C-Trend® -Analysis Tool, Integrated into Bittium BrainStatus™ EEG-System, Receives Medical Device Approval for European Union

Press Release

Free for release on December 18, 2020 at 9.00 am (CET +1)

Cerenion C-Trend® -Analysis Tool, Integrated into Bittium BrainStatus™ EEG-System, Receives Medical Device Approval for European Union

Oulu, Finland, December 18, 2020 – Cerenion C-Trend® analysis tool, integrated into the Bittium BrainStatus™ EEG system, has received a medical device approval for the European Union (EU). Bittium BrainStatus™ EEG device measures and monitors brain EEG signals. With the help of Cerenion C-Trend® analysis, the brain's state is displayed as a straight-forward and simple-to-interpret numeric value by making use of machine-learning algorithms and artificial intelligence. The solution aims to improve care and ease the work of intensive care units' health care staff.

Bittium BrainStatus™ product family received medical device approval in May 2020 (press release May 7, 2020 ). With the Cerenion C-Trend® analysis tool approval, Bittium's entire solution is available for customers in the EU area.

Bittium BrainStatus™ is a wireless EEG measuring system used to monitor electrical activity in the brain in real-time. It is designed for emergency, acute, and intensive care use. Its user-friendliness and high-quality EEG measurement make EEG measurements quick and easy for paramedics and physicians alike.

"Utilizing EEG in the hospital environment has so far been considerably restricted by challenges in both measuring and interpreting the measurements," says Jukka Kortelainen, CEO of Cerenion Oy. "BrainStatus system enables fast and easy EEG measurement. Simultaneously, the C-Trend tool makes available the immediate interpretation and assessment of the brain status measurement also for people without prior EEG experience. It is a perfect combination."

"We are delighted with the Cerenion C-trend® analysis tool's medical device approval. The combination of the Bittium BrainStatus™ system and Cerenion C-Trend® analysis tool create considerable added value for our customers. In neurological emergencies, it is paramount to expedite treatment to prevent permanent damage. When an ICU gets easy and straight-forward tools to measure and assess brain function, it makes health care staff's work more efficient and the treatment process faster for the patient," recounts Arto Pietilä, Senior Vice President of Bittium Medical Technologies.

Cerenion C-Trend® analysis tool is available immediately as a part of the Bittium BrainStatus™ solution.

For more information on Bittium BrainStatus™ -solution, visit .
For more information on the Cerenion C-Trend® tool, visit .


Further information:

Arto Pietilä
Senior Vice President, Medical Technologies
Tel. +358 (0)40 3443507


Main media


Bittium specializes in developing reliable, secure communications and connectivity solutions, leveraging its 30 year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. In healthcare technology, Bittium offers solutions for the measurement and monitoring of biosignals in cardiology, neurophysiology, rehabilitation, occupational health and sports medicine. Net sales in 2019 were EUR 75.2 million, and operating profit was EUR 6.3 million. Bittium is listed on Nasdaq Helsinki.